Provention Bio Inc
NASDAQ:PRVB
| Market Cap (Intraday) | 383.46M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $6.43 |
| 50-Day MA | $7.66 |
| 200-Day MA | $11.89 |
Provention Bio Inc Stock, NASDAQ:PRVB
55 Broad Street, 2nd floor, Red Bank, New Jersey 07701
United States of America
Phone: +1.908.428.9136
Number of Employees:
Description
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn�s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.